NRIX - CIK 0001549595
The table below shows Nurix Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$249.47M | -$172.58M | -$81.36M | -$159.81M | -$84.36M | -$80.00K |
| Capital expenditure | $14.00M | $9.27M | $8.40M | $12.24M | $5.66M | $4.55M |
| Investing cash flow | $147.85M | -$257.71M | $68.30M | $27.20M | -$108.25M | -$254.40M |
| Dividends paid | - | - | - | - | - |
Nurix Therapeutics, Inc. reported operating cash flow of -$249.47M for fiscal year 2025. That is down 44.5% from -$172.58M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from $601.00K (FY 2019) to -$249.47M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $238.64M | $485.67M | $3.22M | $117.19M | $153.88M | $339.02M |